Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2014-12-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib and lapatinib ditoslylate may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of dasatinib and
lapatinib ditoslylate when given together in treating patients with advanced solid tumors
that cannot be removed by surgery.